Key facts
- This page summarizes Amy C. Peterson's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Mar 2023, 18:43.
Amy C. Peterson - 16 Mar 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)
- Reporting relationship
- EVP, Chief Development Officer
- Issuer ticker
- CTMX
- Reported as of
- 16 Mar 2023
- Net transaction value
- -$8,425
- SEC form
- 4
- Accepted by SEC
- 20 Mar 2023, 18:43:26 UTC
- Prior SEC filing
- 21 Jul 2022
- Next SEC filing
- 25 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lloyd Rowland, as Attorney-in-Fact for Amy C. Peterson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amy C. Peterson filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 20 Mar 2023.
Change
- Previous filing in this sequence was filed on 21 Jul 2022.
- Current net transaction value: -$8,425.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTMX
transaction
Common Stock
Sale
- Transaction value
- $8,425
- Shares
- -4,257
- Change %
- -6.8%
- Price
- $1.98
- Shares after
- 58,433
- Date
- 16 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
Footnote F2
Includes 30,000 restricted stock units.